Ikena Oncology grabs $120m Series B

Ikena Oncology Inc, a developer of patient-directed, biomarker-driven cancer therapies, has secured $120 million in Series B financing.

Ikena Oncology Inc, a developer of patient-directed, biomarker-driven cancer therapies, has secured $120 million in Series B financing. Omega Funds led the round with participation from other investors that included Fidelity Management & Research Company, LLC, Surveyor Capital, Invus, Farallon Capital Management, BVF Partners, L.P., Cowen Healthcare Investments, Logos Capital and HealthCor Management.

Source: Press Release